IMMUNE RESPONSE REPORTS IR103 DATA

A A

The Immune Response Corporation has announced that preliminary Phase II study results of its second-generation HIV immunotherapy, IR103, demonstrated a positive safety profile and enhanced immunomodulatory effects over Remune, the company's first-generation immunotherapy.

IR103 differs from currently available antiretroviral drug therapies in that it is an immune-based therapy designed to replenish and enhance key immune cells that have been destroyed by the virus, thus allowing stimulation of an HIV-infected individual's immune system to fight the virus.